Publication

Video

Supplements and Featured Publications

Emerging Treatments and Clinical Challenges in Myelodysplastic Syndromes: ASCO 2021 and EHA 2021 Updates
Volume1
Issue 1

Dr. Sallman on the Efficacy of Pevonedistat Plus Azacitidine in Higher-Risk MDS

David Sallman, MD, discusses the efficacy of pevonedistat plus azacitidine in higher-risk myelodysplastic syndrome.

David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, discusses the efficacy of pevonedistat plus azacitidine in higher-risk myelodysplastic syndrome (HR-MDS).

Findings from the randomized, proof-of-concept phase 2 study (NCT02610777) demonstrated a clinically meaningful improvement in overall survival and event-free survival with the combination of pevonedistat plus azacitidine vs azacitidine alone in patients with HR-MDS/chronic myelomonocytic leukemia or low-blast acute myeloid leukemia, Sallman says.

The overall response rate (ORR) was 70.9% with pevonedistat/azacitidine vs 60.4% with azacitidine alone in the overall patient population. The ORR was 79.3% vs 56.7%, respectively, for patients with HR-MDS. The median duration of response was 34.6 months compared with 13.1 months, respectively, in patients with HR-MDS, Sallman concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity